secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lexeo Therapeutics, Inc. (LXEO)
CIK:        0001907108
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0000950170-25-004566
Event type: other_material
Sentiment:  neutral
Materiality: 0.10
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexeo Therapeutics posts updated corporate presentation; no material new information in 8-K
--------------------------------------------------------------------------------

- Updated corporate presentation posted on website January 13, 2025, for investor and analyst meetings.
- Presentation includes forward-looking statements on gene therapy trial plans and data timing.
- No financial results, leadership changes, or other material events disclosed in this filing.
- Risk factors from prior SEC filings are incorporated by reference.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1907108/000095017025004566/0000950170-25-004566-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1907108/000095017025004566/lxeo-20250113.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-004566

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer